ATLASOutlook Therapeutics (OTLK) earnings date: Dec 18, 2026
Outlook Therapeutics (OTLK) reports earnings for the quarter ended Sep 30, 2026 on Fri, Dec 18, 2026, before the open. Analysts expect EPS of -$0.08.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on OTLK
| Last price | $0.47 (+0.3%) |
|---|---|
| Normal 1-day range (±1σ) | ±5.5% |
| Earnings beat history | Beat the EPS estimate in 0 of the last 4 reports |
These figures come from the same calibrated model and valuation as the Outlook Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Outlook Therapeutics reports on Dec 18, 2026. One email the day before, with ATLAS’s read on Outlook Therapeutics. You can switch it off at any time.
Alert me before OTLK reportsFree to start. Creating an account takes under a minute.
Notify me when Outlook Therapeutics reports
Track OTLK free Add Outlook Therapeutics to a free ATLAS watchlist and see its next report date in one place.
OTLK earnings at a glance
| Next report (confirmed) | Fri, Dec 18, 2026 |
|---|---|
| Time | Before the open |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.08 |
| Last report | Aug 14, 2026 · Miss |
| Beat rate (last 4 reports) | 0 of 4 (0%) |
| Average EPS surprise | -43.6% |
| Average move around a report | ±11.1% (last 4) |
| Sector | Healthcare · Biotechnology |
Outlook Therapeutics earnings history: last 4 reports
Outlook Therapeutics last reported on Aug 14, 2026: EPS of -$0.09 against an estimate of -$0.07 (-28.6% surprise), a miss.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 14, 2026 | -$0.07 | -$0.09 | -28.6% | Miss | -24.4% |
| Jun 25, 2026 | -$0.14 | -$0.16 | -14.3% | Miss | +1.8% |
| May 15, 2026 | -$0.12 | -$0.17 | -41.7% | Miss | -1.7% |
| Feb 17, 2026 | -$0.20 | -$0.38 | -90.0% | Miss | -16.3% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for OTLK
See the fair value, the probability range and the earnings history of Outlook Therapeutics on its ATLAS page.
Outlook Therapeutics (OTLK) stock analysisPlans from €3.99 a month.
Outlook Therapeutics earnings: frequently asked questions
When does Outlook Therapeutics (OTLK) report earnings?
Outlook Therapeutics is scheduled to report on Friday, December 18, 2026, before the open. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for OTLK?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.08 per share (USD). Estimates can change before the report.
How often does OTLK beat earnings estimates?
Of its last 4 reports with a recorded result, Outlook Therapeutics beat the EPS estimate 0 times; the average surprise was -43.6%. Past results do not predict the next one.
How much does OTLK move around earnings?
Over its last 4 reports the stock moved an average of 11.1% (absolute, from the close before the report day to the close after it), and finished higher 1 of 4 times.
Did Outlook Therapeutics beat earnings estimates last quarter?
Outlook Therapeutics last reported on Aug 14, 2026: EPS of -$0.09 against an estimate of -$0.07 (-28.6% surprise), a miss.
How much does OTLK usually move in a day?
On a normal trading day the ATLAS model puts OTLK’s one-day range at about ±5.5%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Fri, Dec 18, 2026
Educational information, not investment advice. Disclaimer